COSCIENS Biopharma Inc.
CSCIF
$5.64
$0.356.52%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.89M | 7.39M | 8.94M | 9.33M | 8.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.89M | 7.39M | 8.94M | 9.33M | 8.92M |
| Cost of Revenue | 4.97M | 4.89M | 5.00M | 4.98M | 4.72M |
| Gross Profit | 2.92M | 2.50M | 3.94M | 4.35M | 4.19M |
| SG&A Expenses | 8.48M | 9.67M | 5.93M | 6.83M | 7.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.44M | 16.87M | 15.57M | 18.70M | 19.69M |
| Operating Income | -7.55M | -9.48M | -6.62M | -9.38M | -10.78M |
| Income Before Tax | -6.88M | -9.37M | -12.84M | -16.89M | -16.09M |
| Income Tax Expenses | 11.00K | 11.00K | 1.08M | 971.00K | 496.00K |
| Earnings from Continuing Operations | -6.89 | -9.38 | -13.93 | -17.86 | -16.58 |
| Earnings from Discontinued Operations | 10.94M | -981.00K | -981.00K | -981.00K | -981.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.05M | -10.36M | -14.91M | -18.84M | -17.56M |
| EBIT | -7.55M | -9.48M | -6.62M | -9.38M | -10.78M |
| EBITDA | -8.71M | -10.66M | -5.68M | -8.24M | -9.55M |
| EPS Basic | 3.95 | -9.81 | -14.19 | -18.03 | -17.40 |
| Normalized Basic EPS | -3.92 | -5.40 | -3.39 | -5.12 | -5.12 |
| EPS Diluted | 3.94 | -9.81 | -14.19 | -18.03 | -17.40 |
| Normalized Diluted EPS | -3.92 | -5.40 | -3.39 | -5.12 | -5.12 |
| Average Basic Shares Outstanding | 4.23M | 4.23M | 4.21M | 4.19M | 3.87M |
| Average Diluted Shares Outstanding | 4.23M | 4.23M | 4.21M | 4.19M | 3.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |